Download PDF
Thromb Haemost 1975; 34(03): 709-717
DOI: 10.1055/s-0038-1651463
Original Article
Schattauer GmbH

Determination of Human Fibrinopeptide A by Radioimmunoassay in Purified Systems and in the Blood[*]

A. Z Budzynski
1   Department of Medicine and the Specialized Center of Research in Thrombosis, Temple University Health Sciences Center, Philadelphia, Pennsylvania, 19140, USA
,
V. J Marder
1   Department of Medicine and the Specialized Center of Research in Thrombosis, Temple University Health Sciences Center, Philadelphia, Pennsylvania, 19140, USA
› Author Affiliations
Further Information

Publication History

Received 12 July 1975

Accepted 12 July 1975

Publication Date:
02 July 2018 (online)

    Permissions and Reprints

Summary

The formation of fibrin clots or circulating soluble fibrin is accompanied by the appearance of fibrinopeptides. Measurement of the fibrinopeptide concentration in plasma can provide important information on the rate of conversion of fibrinogen to fibrin by thrombin. This rate varies under different physiologic and pathologic conditions. Fibrinopeptide A is a better molecular marker of the conversion than fibrinopeptide B since it is the first peptide to be cleaved by thrombin. A radioimmunoassay technique has been developed for the quantitative determination of human fibrinopeptide A. The procedure detects human fibrinopeptide A at a concentration of approximately 0.05 ng/ml. The fibrinopeptide A concentration in plasma of normal persons was found to be approximately 0.5 ng/ml. The variation of fibrinopeptide A content in normal persons may reflect its rapid formation and catabolism. A significantly increased concentration of this peptide was found in a patient during defibrination therapy with a purified enzyme from the venom of Agkistrodon rho-dostoma and in patients suffering from retinal vascular occlusions.

* Presented at the Postgraduate Course and Workshop “Progress in Fibrinolysis”, Milano, Italy, March 6–8, 1975.


 

  • References

  • 1 Bailey K, Bettelheim F. R, Lorano L, and Middlebrook W. R. 1951; Action of thrombin in the clotting of fibrinogen. Nature (London) 167: 233.
    CrossrefPubMedGoogle Scholar
  • 2 Bettelheim F. R, and Bailey K. 1952; The products of the action of thrombin on fibrinogen. Biochimica Biophysica Acta 9: 578.
    PubMedGoogle Scholar
  • 3 Blombäck B, Blombäck M, Edman P, and Hessel B. 1966; Human fibrinopeptides. Isolation, characterization and structure. Biochimica Biophysica Acta 115: 371.
    PubMedGoogle Scholar
  • 4 Blombäck B, and Yamashina I. 1958; On the N-terminal amino acids in fibrinogen and fibrin. Arkiv Kemi 12: 299.
    PubMedGoogle Scholar
  • 5 Budzynski A. Z. 1969; Structure of fibrinogen in relation to its proteolytic degradation products. Postepy Higieny i Medycyny Doswiadczalnej 23: 293.
    PubMedGoogle Scholar
  • 6 Budzynski A. Z, Marder V. J, and Shainoff J. R. 1974; Structure of plasmic degradation products of human fibrinogen. Fibrinopeptide and polypeptide chain analysis. Journal of Biological Chemistry 249: 2294.
    PubMedGoogle Scholar
  • 7 Budzynski A. Z, and Marder V. J. 1973; Solid phase synthesis of human fibrinopeptides A and B. Protides of Biological Fluids 20: 287.
    PubMedGoogle Scholar
  • 8 Budzynski A. Z, Marder V. J, and Sherry S. 1975; Reaction of plasmic degradation products of fibrinogen in the radioimmunoassay of human fibrinopeptide A. Blood 45: 757.
    PubMedGoogle Scholar
  • 9 Dayhoff M. O. 1972 Atlas of Protein Sequence and Structure. National Biomedical Research Foundation, Silver Spring, Maryland. Vol. 5, pp. D 95, D 96.
    PubMedGoogle Scholar
  • 10 Fletcher A. P, Alkjaersig N, O’Brien J, and Tulevski V. G. 1970; Blood hypercoagulability and thrombosis. Transactions of the Association of American Physicians 83: 159.
    PubMedGoogle Scholar
  • 11 Fletcher A. P, Alkjaersig N, and Sherry S. 1962; Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (“fibrinolytic”) states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products. Journal of Clinical Investigations 41: 896.
    CrossrefPubMedGoogle Scholar
  • 12 Folk J. E, Gladner J. A, and Laki K. 1959; The thrombin induced formation of co-fibrin. II. Preliminary amino acid sequence studies on peptides A and B. Journal of Biological Chemistry 234: 67.
    PubMedGoogle Scholar
  • 13 Gerrits W. B. J, Flier O. T. N, and van der Meer J. 1974; Fibrinopeptide A immunoreactivity in human plasma. Thrombosis Research 5: 197.
    CrossrefPubMedGoogle Scholar
  • 14 Gladner J. A, Folk J. E, Laki K, and Carroll W. R. 1959; Thrombin-induced formation of co-fibrin. I. Isolation, purification and characterization of co-fibrin. Journal of Biological Chemistry 234: 62.
    PubMedGoogle Scholar
  • 15 Hunter W. M, and Greenwood F. C. 1962; Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 194: 495.
    CrossrefPubMedGoogle Scholar
  • 16 Lahiri B, and Shainoff J. R. 1972; Fate of fibrinopeptides in the reaction between human plasmin and fibrinogen. Biochimica Biophysica Acta 303: 161.
    PubMedGoogle Scholar
  • 17 Larrieu M. J, Marder V. J, and Inceman S. 1966; Effects of fibrinogen degradation products on platelets and coagulation. Thrombosis et Diathesis Haemorrhagica Suppl.20: 215.
    PubMedGoogle Scholar
  • 18 Larrieu M. J, Rigollot C, and Marder V. J. 1972; Comparative effects of fibrinogen degradation Fragments D and E on coagulation. British Journal of Haematology 22: 719.
    CrossrefPubMedGoogle Scholar
  • 19 Latallo Z. S, Fletcher A. P, Alkjaersig N, and Sherry S. 1962; Inhibition of fibrin polymerization by fibrinogen proteolysis products. American Journal of Physiology 202: 681.
    PubMedGoogle Scholar
  • 20 Latallo Z. S, Budzynski A. Z, Lipinski B, and Kowalski E. 1964; Inhibition of thrombin and of fibrin polymerization, two activities derived from plasmin-digested fibrinogen. Nature 203: 1184.
    CrossrefPubMedGoogle Scholar
  • 21 Lipinski B, Wegrzynowicz Z, Budzynski A. Z, Kopec M, Latallo Z. S, and Kowalski E. 1967; Soluble unclottable complexes formed in the presence of fibrinogen degradation products (FDP) during the fibrinogen-fibrin conversion and their potential significance in pathology. Thrombosis et Diathesis Haemorrhagica 17: 65.
    PubMedGoogle Scholar
  • 22 Lorano L. 1952; Fibrino-peptide. Biochemical Journal 52: 200.
    CrossrefPubMedGoogle Scholar
  • 23 Marder V. J, and Budzynski A. Z. 1971; Classification of fibrinogen derivatives. Thrombosis et Diathesis Haemorrhagica Suppl.51: 267.
    PubMedGoogle Scholar
  • 24 Marder V. J, and Budzynski A. Z. 1975; Data for defining fibrinogen and its plasmic degradation products. Thrombosis et Diathesis Haemorrhagica 33: 199.
    PubMedGoogle Scholar
  • 25 Marder V. J, Shulman N. B, and Carroll W. B. 1969; a High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization. Journal of Biological Chemistry 244: 2111.
    PubMedGoogle Scholar
  • 26 Marder V. J, Shulman N. B. 1969; b High molecular weight derivatives of human fibrinogen produced by plasmin. II. Mechanism of their anticoagulant activity. Journal of Biological Chemistry 244: 2120.
    PubMedGoogle Scholar
  • 27 Marshall G. B, and Merrifield R. B. 1965; Synthesis of angiotensins by the solid-phase method. Biochemistry 4: 2394.
    CrossrefPubMedGoogle Scholar
  • 28 Merrifield R. B. 1963; Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. Journal of the American Chemistry Society 85: 2149.
    CrossrefPubMedGoogle Scholar
  • 29 Merrifield R. B. 1964; Solid phase peptide synthesis. III. An improved synthesis of bradykinin. Biochemistry 3: 1385.
    CrossrefPubMedGoogle Scholar
  • 30 Nossel H. L, Younger L. R, Wilner G. D, Procupez T, Canfield R. E, and Butler Jr. V. P. 1971; Radioimmunoassay of human fibrinopeptide A. Proceedings of the National Academy of Sciences 68: 2350.
    CrossrefPubMedGoogle Scholar
  • 31 Nossel H. L, Yudelman L, Canfield R. E, Butler Jr. V. P, Spanondis K, Wilner G. D, and Qureshi G. D. 1974; Measurement of fibrinopeptide A in human blood. Journal of Clinical Investigation 54: 43.
    CrossrefPubMedGoogle Scholar
  • 32 Schick A. F, and Singer S. J. 1961; On the formation of covalent linkages between two protein molecules. Journal of Biological Chemistry 236: 2477.
    PubMedGoogle Scholar
  • 33 Shainoff J. R, Lahiri B, and Bumpus F. M. 1970; Ultracentrifuge studies on the reaction between thrombin and plasminized fibrinogen. Thrombosis et Diathesis Haemorrhagica 39: 203.
    PubMedGoogle Scholar
  • 34 Shainoff J. R, and Page I. H. 1960; Cofibrins and fibrin-intermediates as indicators of thrombin activity, in vivo. Circulation Research 8: 1013.
    CrossrefPubMedGoogle Scholar
  • 35 Smith G. F, and Bang N. U. 1972; Formation of soluble fibrin polymers. Fibrinogen degradation fragments D and E fail to form soluble complexes with fibrin monomer. Biochemistry 11: 2958.
    CrossrefPubMedGoogle Scholar
  • 36 Wessler S, and Stehbens W. E. 1971. Thrombosis. In: Bang N. U, Beller F. K, Deutsch E, and Mammen E. F. (eds.) Thrombosis and Bleeding Disorders. Academic Press; New York: 488.
    CrossrefGoogle Scholar